BioMarin Pharmaceutical | BMRN - Operating Expenses


BioMarin Pharmaceutical reported $807.82M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 129.75M 9.76M Sep/2025
Alnylam Pharmaceuticals USD 881.04M 91.16M Sep/2025
Amgen USD 5.13B 1.39B Sep/2025
Bayer EUR 10.2B 523M Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Gilead Sciences USD 4.26B 95M Sep/2025
Incyte USD 4.65B 3.75B Sep/2025
Insmed USD 403.69M 42.4M Sep/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Moderna USD 1.28B 232M Sep/2025
Neurocrine Biosciences USD 555.6M 13.7M Sep/2025
PTC Therapeutics USD 207.52M 6.21M Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 10.71B 1.32B Dec/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025
United Therapeutics USD 6.59B 6.07B Sep/2025
Vertex Pharmaceuticals USD 1.84B 27.1M Sep/2025